Business Wire

Exelixis Announces Initiation of Phase 1 Trial Evaluating XL102 as a Single Agent and in Combination with Other Anti-Cancer Agents in Patients with Advanced or Metastatic Solid ...

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (NASDAQ: EXEL) today announced initiation of the first-in-human phase 1 trial evaluating the safety, tolerability, pharmacokinetics and preliminary ...
Business Wire

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a ...
ascopubs.org

A phase 1 dose-escalation and expansion-cohort study of the oral CDK7 inhibitor XL102 as a single-agent and in combination therapy in patients (pts) with advanced solid tumors.

A first-in-human phase I dose-escalation trial of the B7-H6/CD3 T-cell engager BI 765049 ± ezabenlimab (BI 754091) in patients with advanced solid tumors expressing B7-H6. Background: XL102 is an ...
Indiatimes

Exelixis in-licences CKD7 inhibitor XL102 developed by Dr Reddy's arm Aurigene

Pharma major Dr Reddy’s Laboratories on Tuesday informed the bourses that US-based Exelixis Inc has in-licenced Aurigene Discovery Technologies Ltd’s novel CDK7 inhibitor XL102 (formerly AUR102) and ...
Nasdaq

Exelixis In-Licenses Aurigene’s Novel CDK7 Inhibitor and Files Investigational New Drug Application for Phase 1 Clinical Trial in Advanced Solid Tumors

– Promising preclinical data support further advancement of XL102 (formerly AUR102) alone or in combination with chemotherapy – ...
Zonebourse

Exelixis, Inc. Annonce des premiers résultats de l'escalade de dose du premier essai de phase 1 sur l'homme évaluant XL102 chez des patients atteints de tumeurs solides ...

Exelixis, Inc. a annoncé les premiers résultats de la phase d'escalade de dose en cours de QUARTZ-101, un essai clinique de phase 1 évaluant XL102, une petite molécule puissante, sélective, ...
streetinsider

Exelixis Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. – In the QUARTZ-101 trial, XL102 — a novel cyclin-dependent kinase 7 inhibitor — was ...
streetinsider

Exelixis (EXEL) Announces Initial Dose-Escalation Results from the First-in-Human Phase 1 Trial Evaluating XL102 in Patients with Advanced Solid Tumors at SABCS 2022

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here. Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing ...